Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943337 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL43171 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL1267270 | 1.00 | HTR6 (0.64) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL8695162 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Piperazine SCHEMBL27903046 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL28809524 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL572044 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Water SCHEMBL14860181 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL6499302 | 0.97 | HTR6 (0.61) | HTR6KMT2AHPGDSMN1; SMN2HRH3 | |
| SCHEMBL271868 | 0.97 | HTR6 (0.67) | HTR6KMT2AHPGDSMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790887-B2 | Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-09-07 | — | — | US | claimed |
| EP-2116542-A1 | SOLID OF MACROLIDE COMPOUND, METHOD FOR PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-11-11 | — | — | EP | claimed |
| US-20080214564-A1 | MACROLIDE COMPOUND IN SOLID FORM, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-04 | — | — | US | claimed |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2024-03-12 | — | — | US | disclosed |
| EP-4105207-A1 | QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| EP-3774760-A1 | PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER | Eisai R&D Management Co., Ltd. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-107286174-B | Substituted 2,4- (1H,3H) pyrimidinedione as PARP inhibitor and application thereof | 上海勋和医药科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| WO-2019200100-A1 | PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER | COOK ANDREW (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-2927228-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-0322643-B1 | MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | BAYER AG (DE) | 1991-07-24 | — | — | EP | disclosed |
| EP-0426180-A2 | Imidazo[4,5-b] quinolinyloxyalkanoic acid amides with enhanced water solubility | Bristol-Myers Squibb Company (US) | 1991-05-08 | — | — | EP | disclosed |
| US-4943573-A | ENZYME INHIBITORS, CARDIOTONIC, ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4940705-A | VIRICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-10 | — | — | US | disclosed |
| EP-0322643-A1 | Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use | BAYER AG (DE) | 1989-07-05 | — | — | EP | disclosed |
| EP-0313974-A1 | N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals | BAYER AG (DE) | 1989-05-03 | — | — | EP | disclosed |
| US-4417052-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; VIRICIDES | STERLING DRUG INC. (US) | 1983-11-22 | — | — | US | disclosed |
| US-4308382-A | ANTIINFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1981-12-29 | — | — | US | disclosed |
| US-4216326-A | Intermediates for preparing anti-inflammatory phenyl-lower-alkylamines | STERLING DRUG INC. (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214564-A1 | MACROLIDE COMPOUND IN SOLID FORM, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | CYP4A22, CYP2C19, CYP4A11 | HTR6 2065/4885KMT2A 1557/4885HPGD 1123/4885 |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | HTR6 4349/4885KMT2A 3600/4885HPGD 1934/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | HTR6 4219/4885KMT2A 2538/4885HPGD 2590/4885 |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | PLAAT5, PLAAT3, PLAAT4 | HTR6 4349/4885KMT2A 3600/4885HPGD 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.